BioAge prices $198M IPO, validating pivot to obesity drug research
BioPharma Drive: Drug Pricing
SEPTEMBER 25, 2024
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
Let's personalize your content